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Materials and methods..  Lot of patients: 27 patients with endometrial ovarian tumors who 
were hospitalized and received treatment at PMSI OI of the Republic of Moldova between 
2014 and 2019.   
Results. Total number of patients enrolled in the study: 27 patients, 25-45 years (age of highest 
incidence) - 15 patients (55,5%). The most frequent symptoms: pelvic pain - 27 patients 
(100%), dysmenorrhea - 9 patients (33,3%), dyspareunia- 5 patients (18,51%), metrorrhagia - 
3 patients (11,1%).Bimanual examination of 12 patients (44,4%), revealed a smooth, elastic 
mass. According to laboratory data, 19 patients (70,37%) showed high CA 125 values, and 14 
patients (51,8%) high estradiol values. Diagnostic imaging: ultrasound - 27 patients (100%), 
CT -7 patients (25,92%), MRI - 3 patients (11,1%). Laparoscopic methods: diagnostic 
laparoscopy - 12 patients (44,4%). All patients have received surgical treatment: surgery under 
laparoscopy - 12 patients (44,4%), laparotomy - 15 patients (55,5%).   
Conclusions.  1.Age and high estrogen levels are among the main factors which lead to 
endometrial ovarian tumors.  2.Pelvic pain is the main symptom shown by patients followed 
by dysmenorrhea, dyspareunia, and metrorrhagia.  3.Laparoscopy is the golden standard in the 
diagnosis of endometrial ovarian tumors.   
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Introduction.  Metastatic ovarian cancer is a serious worldwide public health problem, with 
one of the highest potential for lethality among all tumors. It is an advanced malignancy, or 
secondary tumor, with primary other organs, most commonly the gastrointestinal tract and 
mammary gland, stomach, colon, appendix, uterus, lung. At present, the treatment of metastatic 
ovarian tumors consists of several successive stages: surgical treatment, chemotherapy and 
radiotherapeutic treatment. Patients with a metastatic limit only in the ovary have a favorable 
prognosis, or usually. Adjuvant chemotherapy after metastasis resection offers survival 
benefits in gastric and colorectal cancer. The ovary is a frequent site of involvement for 
metastases. Ovarian involvement is observed at autopsy in approximately 10% of breast cancer 
cases. Metastasis is bilateral around 80% of patients. About 5-30% of ovarian cancers are 
metastatic malignancies.   
Aim of the study.  To study the techniques and principles of treatment for metastatic ovarian 
tumors   
Materials and methods..  Lot of patients: 53 patients with metastatic ovarians tumors were 
hospitalized and treated in IMSP IO from Moldova during 2012-2019   
Results. Total enrolled: 53 patients, age with the highest incidence - 41-50 years - 18 patients 
(33.9%) Histological distribution: signet ring cell - 26 patients( 49.1%), adenocarcinoma – 24 
patients ( 45.2%), clear cell carcinoma - 3 patients (5.66%). After the primary outbreak - the 
highest incidence for the stomach cancer - 25 patients (47.1%) and uterus cancer- 17 patients 
(32.07%).For the colorectal cancer the incidence is 9.43%- 5 patients, uterin cervical cancer-
3.77%- 2 ,mammary gland cancer-5,66%- 3 patients and for cancer without clarification-1,88 
%- 1 patient. Bilaterality is prevalent in our study with 62.2% (33 persons)  Of them treated 
surgically: 53 patients-100% ,treated only with adjuvant chemotherapy: 40 patints- 75,47 %, 
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treated only with radiotherapy- 7 patients- 13.2 %, combined treatment- 6 patients- 11,3%. 
Chemotherapy treatment consists of complex treatment regimens containing at least 2 
chemotherapeutic preparations. The patients has be treated with fluorouracil, doxorubicin, 
cisplatin, cyclophosphamide .We can mention that fluorouracil was used by 28 patients, 
doxorubicin-24, cisplatin -30, cyclophosphamide-14.   
Conclusions.  Treatment for metastatic cancer aims to slow the growth or spread of the cancer. 
The treatment depends on the type of cancer, where it started, the size and location of the 
metastasis, and other factors. Even if metastatic cancer has stopped responding to treatment, 
many therapies may help ease side effects and improve quality of life.   
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Introduction. Breast cancer is the most common cancer diagnosed in women worldwide, with 
nearly 1.7 million new cases diagnosed annually (25% of the total) and 571,000 deaths. In 
Europe, breast cancer accounts for the highest share (26.4%) of all cancers in women, with 
522,513 new cases, far above colon cancer (11.5%; 228,067 new cases) and lung cancer (8%; 
158,196 new cases). The incidence of breast cancer in Moldova in 2018 was 1125, and the 
morbidity was 360.6 per 100 thousand population.  
Aim of the study. This study aims to analyze the clinical evolution and treatment of breast 
cancer at different stages in young women.   
Materials and methods.. The study is based on a retrospective descriptive analysis carried out 
for about 3 years. The group included 63 patients, all women between the ages of 24 and 45, 
diagnosed with breast cancer at various stages. Clinical evolution, stage, tumor size, 
preoperative treatment and surgical method were evaluated.  
Results. We found that of 63 patients, 61 had clinical symptoms, while 2 patients were 
diagnosed during screening. The complaints of the patients included palpation of a hard, 
immobile, painless tumor of irregular outline – 50 cases (82%); breast swelling – 8 cases 
(13%); nipple leaks – 2 cases (3%), pain – 1 case (2%). Tumor sizes ranged from 1.0 cm to 5.5 
cm. Thirty-eight patients had tumors smaller than 2 cm, 24 patients had tumors with sizes 
between 2 and 5 cm and 1 patient had tumor of 5.5 cm. There were diagnosed 3 patients (5%) 
with stage I; 13 patients (21%) with stage IIA; 39 patients (62%) with stage IIB; 4 patients 
(6%) with stage IIIA; 4 patients (6%) with stage IIIB. Out of 63 patients, 42 patients (67%) 
received preoperative treatment: chemotherapy – 39 patients (61.9%), radiotherapy – 3 patients 
(4.7%). Of the patients receiving chemotherapy, 5 patients took 2 courses, 16 patients – 3 
courses, 14 patients – 4 courses, 2 patients – 6 courses, 2 patients – 8 courses. Surgical 
treatment of malignancies was performed by two methods: single mastectomy – 18 malignant 
tumors (28.5%), Madden radical mastectomy – 45 malignant tumors (71.5%).  
Conclusions. We found that of 63 patients, 61 had clinical symptoms, while 2 patients were 
diagnosed during screening. The complaints of the patients included palpation of a hard, 
immobile, painless tumor of irregular outline – 50 cases (82%); breast swelling – 8 cases 
